Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.

Item
http://www.wikidata.org/entity/Q33373135
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.Emerging agents for the treatment of mantle cell lymphoma.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.How to manage mantle cell lymphoma.Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
P2860

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.

Item
http://www.wikidata.org/entity/Q33373135
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@ast
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
type
label
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@ast
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
prefLabel
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@ast
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921